Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Public ClinicalTrials.gov record NCT07170917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS. Study details include: The study duration (per participant) will be up to approximately 164 weeks for participants transitioning into the long-term extension (LTE) period and will be up to approximately 60 weeks for participants not transitioning into the LTE period. The randomized treatment duration will be up to approximately 152 weeks
Study identification
- NCT ID
- NCT07170917
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 208 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 5, 2025
- Primary completion
- Feb 8, 2027
- Completion
- Nov 22, 2029
- Last update posted
- Aug 19, 2026
2025 – 2029
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Medical Dermatology Specialists - Site Number: 8400019 | Phoenix | Arizona | 85006 | Recruiting |
| Mayo Clinic in Arizona - Scottsdale- Site Number : 8400014 | Scottsdale | Arizona | 85259 | Recruiting |
| Northridge Clinical Trials - Northridge- Site Number : 8400005 | Northridge | California | 91325 | Recruiting |
| FXM Clinical Research - Miami- Site Number : 8400017 | Miami | Florida | 33175 | Recruiting |
| FXM Clinical Research - Miramar- Site Number : 8400004 | Miramar | Florida | 33027 | Recruiting |
| Advanced Medical Research - Atlanta- Site Number : 8400011 | Atlanta | Georgia | 30342 | Recruiting |
| Georgia Skin & Cancer Clinic- Site Number : 8400009 | Savannah | Georgia | 31419 | Recruiting |
| The Iowa Clinic West Des Moines Campus- Site Number : 8400007 | West Des Moines | Iowa | 50266 | Recruiting |
| Louisiana Dermatology Associates- Site Number : 8400006 | Baton Rouge | Louisiana | 70809 | Recruiting |
| Washington University- Site Number : 8400010 | St Louis | Missouri | 63110 | Recruiting |
| JDR Dermatology Research - Site number: 8400012 | Las Vegas | Nevada | 89145 | Recruiting |
| Clinical Partners- Site Number : 8400002 | Johnston | Rhode Island | 02919 | Recruiting |
| AMR Clinical South Strand, South Carolina- Site Number : 8400018 | Myrtle Beach | South Carolina | 29588 | Recruiting |
| UT Southwestern Medical Center, Department of Dermatology- Site Number : 8400022 | Dallas | Texas | 75235 | Recruiting |
| Alpine Research Association- Site Number : 8400008 | Layton | Utah | 84041 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07170917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07170917 live on ClinicalTrials.gov.